Research & development

The Program operates at the interface between scientific advances and the maturation of technologies aimed at delivering solutions that meet the demands of the health system. Its portfolio includes prospecting potential molecular targets as new therapeutic options for the development of pharmaceuticals and biopharmaceuticals, developing organ prototypes and artificial tissues through bioprinting, as well as advancing cell- and/or gene-editing–based therapies to treat diseases of public health relevance.

These studies are carried out across CNPEM’s different units and make use of state-of-the-art scientific facilities, such as beamlines and microscopes, to study macromolecules, cells, and organisms, and to develop and evaluate nanomaterials with biological applications. CNPEM positions itself at the interface between the scientific ecosystem and the productive sector, addressing demands for translating fundamental scientific knowledge into basic inputs required for the industrial sector to carry out the task of producing and leveraging the economic value of health technologies.

Among its deliverables, the Center establishes new competencies dedicated to the biomanufacturing of pilot batches of cell lines that produce monoclonal antibodies and active pharmaceutical ingredients, in compliance with regulatory requirements for good manufacturing practices.